ticasone propionate or budesonide given via a large volume spacer. These results Background -In a previous single dosing emphasise the good safety profile in chilstudy in asthmatic school children fludren of these inhaled steroids at conticasone propionate produced significantly ventional dose levels, which have proven greater suppression of overnight urinary antiasthmatic efficacy. cortisol excretion than budesonide at high (Thorax 1997;52:686-689) doses of 800 g/day or greater. The aim of this study was to assess whether conKeywords: adrenal activity, chronic dosing, inhaled ventional lower doses of both drugs cause corticosteroids, asthmatic children, fluticasone proadrenal suppression when given at steady pionate, budesonide. state twice daily by large volume spacer on a microgram equivalent basis in asthmatic Inhaled corticosteroids have a well established school children.
(95% CI 0.62 to 1.46); fluticasone 100 g bid The aim of this study was therefore to in- 
Conclusions -With repeated twice daily administration at steady state across a
All cases were considered to have stable asthma 20.00 hours, subjects emptied their bladder and collected all their overnight urine for 12 of mild to moderate severity. Their mean forced expiratory volume in one second (FEV 1 ) was hours until 08.00 hours the following morning.
No further steroid or bronchodilator inhalers 1.99 (0.14) l, 78.6 (4.7)% of predicted, and mid forced expiratory flow rate ) was were taken until completion of the urine collection. 2.18 (0.24) l/s, 72.5 (7.5)% of predicted. Both parents and children gave written informed consent. Approval for the study was given by the Tayside medical ethics committee for  Overnight 12 hour urinary free cortisol exmeasurement of overnight urinary cortisol excretion but not plasma cortisol levels. All the cretion and creatinine excretion were measured. The urinary cortisol was measured using children were continent of urine day and night. The subjects were taking 400 g/day or less of a commercial radioimmunoassay kit (Incstar, Wokingham, Berkshire, UK) with an intrainhaled corticosteroid (median dose 400 g/ day), beclomethasone dipropionate (Becodisk) assay and interassay coefficient of variability for analytical imprecision of 9.94% and 9.50%, re-400 g/day (six patients) and fluticasone propionate (Diskhaler) 200 g/day (two patients). spectively. Urinary creatinine was measured on a Cobas-Bio autoanalyser (Roche Products Ltd, None had received oral corticosteroids within the preceding six months.
Welwyn Garden City, Herts, UK) and the intraassay and interassay coefficients of variability for analytical imprecision were 4.55% and 0.63%, respectively. We have previously reported an  A single blind (investigator blind), placebo con-intrasubject coefficient of variation of 5.4% for measurement of overnight urinary cortisol extrolled, randomised crossover design was used with twice daily dosing over four days at each cretion in asthmatic children.
3 dose level. The duration of each treatment was chosen to ensure steady state drug levels. Subjects attended an initial screening visit  
The power of the study was 80% in order where FEV 1 and FEF were measured using a Vitalograph Compact spirometer (Vitalo-to detect a 30% difference from placebo in overnight urinary cortisol excretion on the basis graph Ltd, Buckingham, UK), having withheld inhaled bronchodilators for eight hours. De-of a previous study with budesonide and fluticasone propionate in asthmatic children. 3 All tailed instruction in correct usage of metered dose inhaler (MDI) and spacer combinations data were analysed using a Statgraphics software package (STSC Software Group, Rockwere given according to the manufacturers' recommendations.
ville, Maryland, USA). The data were initially subjected to a plot to assess whether they conSubjects were then randomised to receive treatment for eight days in crossover fashion formed to a normal distribution and were then analysed by comparing the pooled placebo with with either fluticasone propionate (Flixotide MDI, 50 g per actuation, Allen and Hanburys, both drugs at both dose levels using a multifactorial analysis of variance (MANOVA) with Uxbridge, Middlesex, UK), 100 g and 200 g twice daily or budesonide (Pulmicort MDI, treatments, doses, subjects, and periods as factors. This was followed by Bonferroni multiple 50 g per actuation, Astra Pharmaceuticals, Kings Langley, Herts, UK) 100 g and 200 g range testing in order to obviate multiple pairwise comparisons. The urinary cortisol/cretwice daily, each dose being given sequentially for four days. These were given in conjunction atinine ratio data were analysed as trimmed means to account for three outlying data points with their respective large volume spacer (Nebuhaler or Volumatic) according to manu-above a ratio of 20 (these are depicted in fig 2, one for budesonide 100 g bid, one for facturers' instructions, using single puffs with no delay. Correct use of the spacer was checked fluticasone 100 g bid, and one for fluticasone 200 g bid). The cortisol/creatinine data conprior to inclusion into the study as well as at each study visit. Randomisation was in bal-form to a normal distribution when analysed in this way. A probability value of <0.05 (twoanced blocks with four given fluticasone first and four receiving budesonide first. Placebo tailed) was accepted as being significant. Ratios were calculated for the differences between each MDI (plus spacer) was given for four days prior to the start of each of the two eight day active treatment and placebo and expressed as a fold difference with 95% confidence interval (for treatment periods. There was at least a 12 day washout period between the two 12 day intra-individual differences). sequences during which the patients resumed their standard inhaled steroid therapy.
The aerosol canisters and plastic actuators Results There were no significant differences between were masked and placed in identical boxes. Each treatment box was dispensed by a differ-the first and second placebos given in sequence for either overnight urinary cortisol ent person from the investigator in order to keep the investigator blinded. Subjects omitted excretion (that is, placebo 1 versus placebo 2):
22.5 nmol/12 h versus 23.5 nmol/12 h or for their usual steroid inhaler for the duration of each 12 day sequence. Mouth rinsing was per-overnight urinary cortisol/creatinine excretion:
6.84 nmol/mmol versus 6.28 nmol/mmol. formed after each two puffs of their study inhaler. After seven doses at each dose level, There were also no significant differences between placebo values prior to each treatment immediately before taking the eighth dose at group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from compared with placebo. There were also no significant differences between the two drugs. These data are depicted in figs 1 and 2 as means and individual values to show dispersion. The ratios for suppression with active drug versus placebo are shown in table 1 as means and 95% CI for within subject differences. There were two low urinary cortisol results (<10 nmol/12 h), one each for fluticasone 200 g bid and budesonide 200 g bid.
Discussion
The results of this study show that inhaled budesonide and fluticasone propionate at doses up to 200 g twice daily via large volume spacer do not cause any detectable adrenal suppression at steady state using the sensitive marker of overnight urinary cortisol excretion. amounting to 30% or less. Nonetheless, in terms of clinical relevance only one patient with each drug at 200 g twice daily had an abnormally low overnight urinary cortisol excretion (<10 nmol/12 h). These findings should offer reassurance to both clinicians and parents as to the safety of inhaled corticosteroids at conventional low doses in light of recent case reports regarding the adverse effects of high doses of inhaled fluticasone in asthmatic children. 6 It is worth noting that, currently in the UK, the highest licensed recommended daily dose of budesonide in children is 800 g/day compared with 200 g/day for fluticasone propionate.
We have previously found, in asthmatic children, differences between single evening doses of inhaled fluticasone propionate and budesonide of 800 g or more in terms of adrenal suppression, with fluticasone causing detectable suppression whilst budesonide caused ticasone. 6 We have also found similar changes outlying data points with a ratio of >20 which were removed when calculating the trimmed means.
in a single evening dosing comparison of fluticasone and budesonide in adult asthmatics 7 which showed a difference in plasma cortisol levels at 08.00 hours between the drugs at for either urinary cortisol excretion (that is, placebo prior to budesonide versus placebo doses above 1000 g. However, with repeated twice daily dosing in adult asthmatics differprior to fluticasone): 20.9 nmol/12 h versus 24.6 nmol/12 h or for urinary cortisol/cre-ences in suppression of 08.00 plasma cortisol levels occurred with doses as low as 250 g atinine excretion: 6.53 nmol/mmol versus 6.63 nmol/mmol. twice daily with a mean treatment difference of 23% for cortisol suppression at 08.00 hours.
8
The results for overnight urinary cortisol and cortisol/creatinine excretion did not reveal Similar results have also been seen in studies on healthy adult volunteers using plasma cortiany significant suppression with either drug group.bmj.com on June 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from sol AUC 0-20 , revealing an accentuation of the availability and hence systemic activity. 19 In this respect the addition of a Nebuhaler to the MDI differences between fluticasone and budesonide with repeated dosing compared with single for budesonide has been shown to increase the in vitro respirable fraction from 8% to 27% doses.
9 Boorsma et al also found differences between the two drugs in healthy volunteers with using an Andersen sampler in conjunction with an anatomical child throat. 20 Furthermore, in a 20% treatment difference in suppression of plasma cortisol AUC 0-24 at a dose of 200 g vitro data using identical methodology have shown that the respirable fraction for budesontwice daily.
10 These results are explained by the pharmacological properties of these drugs as, ide Turbohaler is 30% 21 so it is likely that the data for budesonide via a Nebuhaler (27% with chronic dosing, the longer plasma elimination half life of fluticasone of 14.4 hours 11 respirable fraction) can be extrapolated to the Turbohaler. compared with 2.3 hours for budesonide 12 and the greater lipophilicity of fluticasone 13 will result In conclusion, we have found that twice repeated daily dosing with inhaled budesonide in greater plasma and tissue retention. This, in conjunction with increased steroid potency and and fluticasone propionate given via a large volume spacer in a dose range of 200-400 g/ affinity for fluticasone, would be expected to accentuate the differences found between flu-day did not cause any detectable adrenal suppression in asthmatic children. ticasone and budesonide from the level of suppression already seen with single dosing.
The absence of detectable adrenal sup-This study was funded by a grant from the Astra Foundation (UK).
pression with chronic dosing in children therefore appears initially to be somewhat surprising Eur J Clin Pharmacol 1996; 49:459-63. doses of these drugs was 800 g whereas the 10 Boorsma M, Andersson N, Larsson P, Ullman A. Ashighest evening dose in the present chronic sessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996; 9:1427-32. dosing study was only 200 g. an MDI and spacer and no changes were seen 16 Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, in plasma cortisol levels at 08.00-10.00 hours. 
